BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 26818835)

  • 21. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.
    Healey MA; Hirko KA; Beck AH; Collins LC; Schnitt SJ; Eliassen AH; Holmes MD; Tamimi RM; Hazra A
    Breast Cancer Res Treat; 2017 Nov; 166(2):613-622. PubMed ID: 28791482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
    Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
    Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer.
    Christgen M; von Ahsen S; Christgen H; Länger F; Kreipe H
    Hum Pathol; 2015 Sep; 46(9):1341-9. PubMed ID: 26206765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma.
    Feng M; Deng Y; Yang L; Jing Q; Zhang Z; Xu L; Wei X; Zhou Y; Wu D; Xiang F; Wang Y; Bao J; Bu H
    Diagn Pathol; 2020 May; 15(1):65. PubMed ID: 32471471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digital immunohistochemistry wizard: image analysis-assisted stereology tool to produce reference data set for calibration and quality control.
    Plancoulaine B; Laurinaviciene A; Meskauskas R; Baltrusaityte I; Besusparis J; Herlin P; Laurinavicius A
    Diagn Pathol; 2014; 9 Suppl 1(Suppl 1):S8. PubMed ID: 25565221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.
    Zhong F; Bi R; Yu B; Yang F; Yang W; Shui R
    PLoS One; 2016; 11(2):e0150505. PubMed ID: 26928407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer.
    Robertson S; Stålhammar G; Darai-Ramqvist E; Rantalainen M; Tobin NP; Bergh J; Hartman J
    J Clin Pathol; 2018 Sep; 71(9):787-794. PubMed ID: 29588372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.
    Abubakar M; Orr N; Daley F; Coulson P; Ali HR; Blows F; Benitez J; Milne R; Brenner H; Stegmaier C; Mannermaa A; Chang-Claude J; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RA; Seynaeve C; Figueroa J; Sherman ME; Lissowska J; Hewitt S; Eccles D; Hooning MJ; Hollestelle A; Martens JW; van Deurzen CH; ; Bolla MK; Wang Q; Jones M; Schoemaker M; Wesseling J; van Leeuwen FE; Van 't Veer L; Easton D; Swerdlow AJ; Dowsett M; Pharoah PD; Schmidt MK; Garcia-Closas M
    Breast Cancer Res; 2016 Oct; 18(1):104. PubMed ID: 27756439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ki 67 assessment in breast cancer in an Egyptian population: a comparative study between manual assessment on optical microscopy and digital quantitative assessment.
    Ayad E; Soliman A; Anis SE; Salem AB; Hu P; Dong Y
    Diagn Pathol; 2018 Aug; 13(1):63. PubMed ID: 30153851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Digital Image Analysis of Ki67 Heterogeneity Improves the Diagnosis and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Zhang M; Tan C; Wang X; Ding X; Zhang B; Yang Z; Wang Y; Sheng W; Huang D
    Mod Pathol; 2023 Jan; 36(1):100017. PubMed ID: 36788066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma.
    Klimowicz AC; Bose P; Nakoneshny SC; Dean M; Huang L; Chandarana S; Magliocco AM; Wayne Matthews T; Brockton NT; Dort JC
    Eur J Cancer; 2012 Sep; 48(14):2166-74. PubMed ID: 22892062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.
    Böger C; Behrens HM; Röcken C
    J Surg Oncol; 2016 Jan; 113(1):46-54. PubMed ID: 26709194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
    Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
    Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.
    Aleskandarany MA; Green AR; Ashankyty I; Elmouna A; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Jul; 158(2):287-95. PubMed ID: 27380874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.